



December 14, 2022

**BSE Limited**

Floor 25, P. J. Towers  
Dalal Street, Fort  
Mumbai - 400 001

**National Stock Exchange of India Limited**

Exchange Plaza  
Bandra Kurla Complex, Bandra (E)  
Mumbai - 400 051

Scrip Code: **530019**

Symbol: **JUBLPHARMA**

Dear Sirs,

We enclose a communication pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

We request you to take the same on record.

Thanking you,

Yours faithfully,  
For Jubilant Pharmova Limited

Naresh Kapoor  
Company Secretary

Encl.: as above

A Jubilant Bhartia Company

OUR VALUES



**Jubilant Pharmova Limited**

1-A, Sector 16-A,  
Noida-201 301, UP, India  
Tel: +91 120 4361000  
Fax: +91 120 4234895-96  
[www.jubilantpharmova.com](http://www.jubilantpharmova.com)

Regd Office:  
Bhartiagram, Gajraula  
Distt. Amroha - 244 223  
UP, India  
CIN : L24116UP1978PLC004624



**Jubilant Pharmova Limited**  
1A, Sector 16A, Noida – 201301, India  
Tel.: +91 120 4361000  
[www.jubilantpharmova.com](http://www.jubilantpharmova.com)

**PRESS RELEASE**

**Noida, Wednesday, December 14, 2022**

**Jubilant Pharmova announces USFDA completes inspection of its  
API Manufacturing Facility at Nanjangud, India**

Jubilant Pharmova Limited today announced that the United States Food and Drug Administration (USFDA) has concluded inspection of the Active Pharmaceutical Ingredients (API) manufacturing facility at Nanjangud on December 13, 2022.

The US FDA has issued eight observations pursuant to the completion of the inspection. The company will submit an action plan on the observations and will engage with US FDA for next steps.

**About Jubilant Pharmova Limited**

Jubilant Pharmova Limited (formerly Jubilant Life Sciences Limited) is a company engaged in Specialty Pharmaceuticals, Contract Research, Development and Manufacturing (CRDMO), CDMO, Generics and Proprietary Novel Drugs businesses. Specialty Pharmaceuticals, CDMO and Generics businesses through Jubilant Pharma Limited Singapore (JPL) is engaged in manufacturing and supply of Radiopharmaceuticals with a network of radiopharmacies in the US, Allergy Immunotherapy, Contract Manufacturing of Sterile Injectables and Non-sterile products and Generics/branded formulations through five manufacturing facilities that cater to all the regulated markets including USA, Europe and other geographies. Jubilant Biosys Limited provides contract research and development services through two world class research centers in Bangalore and Noida in India. Jubilant Pharmova Limited is also involved in manufacturing of Active Pharmaceutical Ingredients (API) from its USFDA approved facility in Nanjangud, India. Jubilant Therapeutics is involved in Proprietary Novel Drugs business and is an innovative biopharmaceutical company developing breakthrough therapies in the area of oncology and autoimmune disorders. Jubilant Pharmova Limited has a team of over 6,000 multicultural people across the globe. The Company is well recognized as a 'Partner of Choice' by leading pharmaceuticals companies globally. For more information, please visit: [www.jubilantpharmova.com](http://www.jubilantpharmova.com)

**For more information, please contact:**

**For Investors**

**Surajit Pal**

Ph: +91 120 436 1002

E-mail: [surajit.pal1@jubl.com](mailto:surajit.pal1@jubl.com)

***Disclaimer***

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the

---



anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Pharmova may, from time to time, make additional written and oral forward looking statements, including statements contained in the company's filings with the regulatory bodies and its reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.

